Case report: Dupilumab leads to an increased chance of head and neck Staphylococcus aureus infection in atopic dermatitis patients

Min Chen; Kai Gao; Kamran Ali; Jinpeng Shan; YunMi Qiu; Tianci Xie; Yiling Yu; Liming Wu

doi:10.3389/fmed.2023.1027589

Case report: Dupilumab leads to an increased chance of head and neck Staphylococcus aureus infection in atopic dermatitis patients

Front Med (Lausanne). 2023 Mar 8:10:1027589. doi: 10.3389/fmed.2023.1027589. eCollection 2023.

Authors

Min Chen¹, Kai Gao¹, Kamran Ali¹, Jinpeng Shan¹, YunMi Qiu¹, Tianci Xie¹, Yiling Yu¹, Liming Wu²

Affiliations

¹ Department of Dermatology, The Fourth School of Medicine Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
² Department of Dermatology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Abstract

Dupilumab was the first biological medication licensed to treat atopic dermatitis (AD), and it has shown remarkable effectiveness and safety in the treatment of moderate-to-severe atopic dermatitis. There are limited drug-related adverse events associated with dupilumab in atopic dermatitis (AD) treatment. Here, we present two cases of local Staphylococcus aureus infection during the treatment of atopic dermatitis with dupilumab.

Keywords: Staphylococcus aureus infection; adverse event; atopic dermatitis; drug reaction; dupilumab adverse reactions.

Publication types

Case Reports